ALTEN Calsoft uses BlockApps STRATO to launch blockchain for clinical trials

ALTEN Calsoft in partnership with Clinlogix launches blockchain for clinical trials

Blockapps Calen

ALTEN Calsoft Labs, an enterprise digital transformation solution and engineering R&D services company, has launched “BioPharma Ledger,” a blockchain clinical trial platform.

The newly created blockchain platform for clinical trials will leverage the BlockApps STRATO middleware platform. BlockApps is a founding member of the Enterprise Ethereum Alliance (EEA), the world’s largest open-source blockchain initiative, and has the distinction as the first blockchain platform available on Microsoft Azure, AWS, and Google Cloud.

This development aims to reinforce ALTEN Calsoft Labs’ continued commitment to bringing digital-led transformation to industry-specific areas. The blockchain practice provides customers with enterprise blockchain solutions in innovative business initiatives covering everything from business strategy and ideation to development and full enterprise scale.

“The blockchain for clinical trials is our first initiative in the broader blockchain practice at ALTEN Calsoft Labs. We will make a significant impact on the clinical trial process with our scalable blockchain platform that will ultimately address many key core processes in the Life Sciences industry. This will pave the way to fundamental changes in other key verticals that will demonstrate savings in costs, time and efficiency – all with the meaningful added benefits of security and trust.”
– Paul Elisii, Vice President of BI and Blockchain, ALTEN Calsoft Labs

Clinlogix, a leading-edge global clinical research organization (CRO), with locations in Europe, Asia, South America, and the US will be the first practitioner to pilot and implement the platform in real-world clinical trials.

“I’m very excited to be one of the first, if not the first, CRO who is moving ahead with the rapid development and deployment of a blockchain-based platform which will become an industry standard. Clinlogix has always embraced new technologies that improve patient outcomes, safety, and health along with helping our sponsors to get new treatments to market rapidly, efficiently and cost-effectively. We are a decidedly different CRO and the new blockchain technology complements our ‘Innovation Pathway’ culture for all of our people and our customers.”
– JeanMarie Markham, the Founder and CEO of Clinlogix

Exit mobile version